Evaluation of thiol/disulfide hemostasis and serum Ischemia modified albumin as oxidative stress biomarkers in systemic lupus erythematosus patients: Relationship with major organ involvement and disease activity

Ermurat, Selime; Kazancı, Elif Güler; Toka, Dilara Isiyel; Ayar, Koray; Eren, Funda; Neşeli̇oğlu, Salim

doi:10.1177/09612033221115628

Cited by 3 publications

(13 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While some studies have demonstrated an increase in IMA levels in rheumatic diseases, there are also studies with conflicting results. Ermurat et al [28] reported no difference in IMA levels between SLE patients and HCs in their study.…”

Section: Discussionmentioning

confidence: 65%

Value of ischemia-modified albumin in ankylosing spondylitis

Orucoglu Yildirim,

Balcı,

Tamer

2023

J Surg Med

View full text Add to dashboard Cite

Background/Aim: Ankylosing spondylitis (AS) is a chronic inflammatory illness with a poorly known pathogenesis. Current biomarkers that are used to estimate inflammation are normal in some patients despite having active disease. Recent studies have revealed that oxidative stress may have a role in AS and that there is a close relationship between oxidative stress and inflammation. Ischemia-modified albumin (IMA) is a promising new biomarker for oxidative stress. Thus, the aim of this study was to assess IMA levels and their relationship with disease activity and other inflammatory markers in patients with AS. Methods: This prospective case-control study included 48 patients with AS and 25 healthy controls (HCs). The measured serum levels of IMA, interleukin (IL)-17, and IL-23 were compared between patients with AS and the HC group. We also analyzed the correlation between IMA and disease activity, acute phase reactants, and HLA-B27 positivity. The Ankylosing Spondylitis Disease Activity Score with C-Reactive Protein (ASDAS-CRP) and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) were used to determine disease activity. Results: There was no difference in serum IMA levels between the AS and HC groups (25.08 [20.49-46.83] vs. 29.89 [29.89-42.0], P=0.146). Only IL-23 was significantly higher in patients with AS (10.81 [7.25-14.06] vs. 7.95 [6.85-10.46], P=0.039). Furthermore, there was no correlation between IMA and IL-23, IL-17, CRP, ESR, BASDAI, or ASDAS-CRP (r=-0.079, P=0.593; r=-0.043, P=0.771; r=-0.018, P=0.906; r=0.047, P=0.751; r=0.281, P=0.053; r=0.162, P=0.271). There was no significant difference between IMA, IL-17, and IL-23 levels in patients with low disease activity (BASDAI <4, ASDAS-CRP <2.1) and high disease activity (BASDAI ≥4, ASDAS-CRP ≥2.1) (BASDAI: P=0.146, P=0.303, P=0.071, and ASDAS-CRP: P=0.451, P=0.410, P=0.324, respectively). There was no difference in IMA levels between HLA-B27-positive patients and HLA-B27-negative patients (P=0.070). Conclusion: Although oxidative stress has been suggested to play a role in AS pathogenesis, we did not find an increase in serum levels of IMA, an oxidative stress biomarker, in patients with AS. Our results suggest that IMA may not be a reliable indicator of inflammation. Further research is needed to determine whether IMA may have a role as a biomarker in AS.

show abstract

Section: Discussionmentioning

confidence: 65%

Value of ischemia-modified albumin in ankylosing spondylitis

Orucoglu Yildirim,

Balcı,

Tamer

2023

J Surg Med

View full text Add to dashboard Cite

show abstract

“…After reviewing the full text of the remaining 22 articles, a further two were excluded because of missing data (one study) and no case‐control design (one study). Therefore, 20 studies were selected for analysis 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 (Table 1 ). The risk of bias was low in 18 studies, 70 , 71 , 72 , 73 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 moderate in one, 75 and high in the remaining one 74 (Table 2 ).…”

Section: Resultsmentioning

confidence: 99%

“…Therefore, 20 studies were selected for analysis 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 (Table 1 ). The risk of bias was low in 18 studies, 70 , 71 , 72 , 73 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 moderate in one, 75 and high in the remaining one 74 (Table 2 ). The cross‐sectional nature of the selected studies primarily accounted for the low initial certainty of evidence (level 2).…”

Section: Resultsmentioning

confidence: 99%

“…Twenty studies, including 21 group comparators, investigated IMA in a total of 1188 RD patients (mean age 45 years, 64% females) and 981 healthy controls (mean age 44 years, 66% females) 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 (Table 1 ). Sixteen studies were conducted in Turkey, 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 82 , 83 , 84 , 85 , 86 , 88 , 89 one in Italy, 70 one in Brazil, 71 one in Egypt, 81 and one in South Korea. 87 Four study groups included patients with AS, 77 , 78 , 86 , 89 four with BD, 74 , 75 , 79 , 85 three with RA, 71 ...…”

Section: Resultsmentioning

confidence: 99%

“… 87 Four study groups included patients with AS, 77 , 78 , 86 , 89 four with BD, 74 , 75 , 79 , 85 three with RA, 71 , 81 , 82 three with FMF, 72 , 76 , 89 one with SSc, 70 one with fibromyalgia, 73 one with IgA vasculitis (IgAV), 80 one with SS, 83 one with osteoarthritis (OA), 84 one with ANCA‐associated vasculitis (AAV), 87 and one with SLE. 88 IMA was measured using the albumin cobalt binding test (ACB) test in 14 group comparators, 73 , 75 , 76 , 77 , 78 , 79 , 80 , 82 , 84 , 85 , 86 , 88 , 89 an enzyme‐linked immunosorbent assay (ELISA) in two, 81 , 87 an automatic analyzer in two, 70 , 71 whereas the remaining three did not report the analytical method used. 72 , 74 , 83 Disease duration, reported in 11 study groups, ranged between 1.7 and 9 years.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Ischemia‐modified albumin in rheumatic diseases: A systematic review and meta‐analysis

Mangoni,

Zinellu

2024

Immunity Inflam & Disease

View full text Add to dashboard Cite

IntroductionThe identification of novel, easily measurable disease biomarkers might enhance the diagnosis and management of patients with rheumatic diseases (RDs). We conducted a systematic review and meta‐analysis of ischemia‐modified albumin (IMA), a marker of oxidative stress, acidosis, and ischemia, in RD patients and healthy controls.MethodsWe searched PubMed, Web of Science, and Scopus from inception to January 15, 2024. The risk of bias and the certainty of evidence were assessed using the Joanna Briggs Institute Critical Appraisal Checklist and GRADE, respectively.ResultsIn 20 studies investigating a total of 1188 RD patients (mean age 45 years, 64% females) and 981 healthy controls (mean age 44 years, 66% females), RD patients had significantly higher IMA concentrations when compared to controls (standard mean difference, SMD = 0.50, 95% CI: 0.18−0.83, p = .003; I2 = 92.4%, p < .001; low certainty of evidence). In subgroup analysis, the pooled SMD was significantly different in studies investigating ankylosing spondylitis (p < .001), Behçet's disease (p < .001), and rheumatoid arthritis (p = .033), but not familial Mediterranean fever (p = .48). Further associations were observed between the pooled SMD and the broad classification of autoimmune and/or autoinflammatory diseases, the study country, and the method used to measure IMA.ConclusionOur study suggests that IMA is a promising biomarker of oxidative stress, acidosis, and ischemia, as it can effectively discriminate between patients with different types of RDs and healthy controls. Our results warrant confirmation in longitudinal studies of patients with different types of RDs and different ethnicities (PROSPERO registration number: CRD42024509126).

show abstract

Biomarkers of Oxidative Stress in Systemic Lupus Erythematosus Patients with Active Nephritis

Liu,

de Leeuw,

Arends

et al. 2023

Antioxidants

View full text Add to dashboard Cite

Oxidative stress plays an important role in systemic lupus erythematosus (SLE) and especially in lupus nephritis (LN). The aim of this study was to compare redox-related biomarkers between patients with active LN, quiescent SLE (Q-SLE) and healthy controls (HC) and to explore their association with clinical characteristics such as disease activity in patients. We investigated levels of plasma free thiols (R-SH, sulfhydryl groups), levels of soluble receptor for advanced glycation end products (sRAGE) and levels of malondialdehyde (MDA) in SLE patients with active LN (n = 23), patients with quiescent SLE (n = 47) and HC (n = 23). Data of LN patients who previously participated in Dutch lupus nephritis studies and longitudinal samples up to 36 months were analyzed. Thiol levels were lower in active LN at baseline and Q-SLE patients compared to HC. In generalized estimating equation (GEE) modelling, free thiol levels were negatively correlated with the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) over time (p < 0.001). sRAGE and MDA were positively correlated with the SLEDAI over time (p = 0.035 and p = 0.016, respectively). These results indicate that oxidative stress levels in LN patients are increased compared to HC and associated with SLE disease activity. Therefore, interventional therapy to restore redox homeostasis may be useful as an adjunctive therapy in the treatment of oxidative damage in SLE.

show abstract

Evaluation of thiol/disulfide hemostasis and serum Ischemia modified albumin as oxidative stress biomarkers in systemic lupus erythematosus patients: Relationship with major organ involvement and disease activity

Cited by 3 publications

References 45 publications

Value of ischemia-modified albumin in ankylosing spondylitis

Value of ischemia-modified albumin in ankylosing spondylitis

Ischemia‐modified albumin in rheumatic diseases: A systematic review and meta‐analysis

Biomarkers of Oxidative Stress in Systemic Lupus Erythematosus Patients with Active Nephritis

Contact Info

Product

Resources

About